Mangoceuticals (MGRX) Depreciation & Amortization (CF) (2023 - 2026)

Mangoceuticals has disclosed Depreciation & Amortization (CF) across 4 years of filings, most recently posting $250.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $250.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1013.0 (down 74.43% YoY), and the FY2025 annual result was $1012.0, down 89.81% from the prior year.
• Depreciation & Amortization (CF) came in at $250.0 for Q1 2026 at Mangoceuticals, down from $255.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $12515.0 in Q3 2023 to a low of $250.0 in Q1 2025.
• The 4-year median for Depreciation & Amortization (CF) is $1856.5 (2024), against an average of $3526.0.
• Across the five-year window, Depreciation & Amortization (CF) increased 2.33% in 2024 and slumped 95.98% in 2025, its largest moves.
• Mangoceuticals' Depreciation & Amortization (CF) stood at $6292.0 in 2023, then sank by 95.95% to $255.0 in 2024, then changed by 0.0% to $255.0 in 2025, then decreased by 1.96% to $250.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $250.0 (Q1 2026), $255.0 (Q4 2025), and $256.0 (Q3 2025), per Business Quant data.